Bvf Inc Portfolio Holdings

Bvf Inc

  • $3.15 Billion
  • Q3 2024

Bvf Inc has filed its 13F form on November 14, 2024 for Q3 2024 where it was disclosed a total value porftolio of $3.15 Billion distributed in 55 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Moon Lake Immunotherapeutics with a value of $1.1B, Kymera Therapeutics, Inc. with a value of $244M, Revolution Medicines, Inc. with a value of $158M, Mirum Pharmaceuticals, Inc. with a value of $120M, and Tyra Biosciences, Inc. with a value of $110M.

Examining the 13F form we can see an decrease of $124M in the current position value, from $3.27B to 3.15B.

Bvf Inc is based out at San Francisco, CA

Below you can find more details about Bvf Inc portfolio as well as his latest detailed transactions.

Portfolio value $3.15 Billion
Healthcare: $3.15 Billion

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
$2.01B
$1.1 Billion 34.86% of portfolio
21,751,284
Q2 2022 New
$2.61B
$244 Million 7.77% of portfolio
5,161,801
Q4 2023 Added 8.92%
$4.54B
$158 Million 5.01% of portfolio
3,478,612
Q3 2024 Reduced 41.84%
$1.7B
$120 Million 3.81% of portfolio
3,075,907
Q3 2024 Reduced 29.61%
$666M
$110 Million 3.48% of portfolio
4,661,194
Q1 2024 Added 70.14%
$413M
$109 Million 3.47% of portfolio
9,135,893
Q3 2023 Added 20.03%
$601M
$96.3 Million 3.06% of portfolio
5,750,683
Q2 2024 Added 79.89%
$371M
$96.2 Million 3.06% of portfolio
3,633,743
Q1 2023 Added 0.62%
$4.25B
$94 Million 2.99% of portfolio
1,046,000
Q3 2024 Added 9.53%
$2.12B
$83.1 Million 2.64% of portfolio
1,850,167
Q3 2024 Reduced 44.26%
$246M
$79.8 Million 2.54% of portfolio
7,382,642
Q3 2024 Added 88.22%
$268M
$73.8 Million 2.35% of portfolio
19,522,436
Q3 2024 Added 3.65%
$452M
$69.6 Million 2.21% of portfolio
10,400,158
Q4 2023 Added 12.13%
$749M
$65.9 Million 2.09% of portfolio
3,371,761
Q3 2024 Reduced 17.4%
$515M
$59.2 Million 1.88% of portfolio
4,365,933
Q4 2022 Added 24.68%
$5.12B
$58.2 Million 1.85% of portfolio
1,451,879
Q3 2024 Reduced 54.43%
$3.23B
$52.9 Million 1.68% of portfolio
1,190,107
Q2 2024 New
$189M
$51.7 Million 1.64% of portfolio
3,466,000
Q2 2024 New
$441M
$50.4 Million 1.6% of portfolio
6,811,631
Q3 2024 Reduced 10.0%
$334M
$49.4 Million 1.57% of portfolio
5,302,000
Q2 2024 New
$1.84B
$45.2 Million 1.44% of portfolio
1,569,422
Q2 2024 Reduced 15.79%
$1.32B
$44.7 Million 1.42% of portfolio
1,409,993
Q3 2024 Added 21.31%
$251M
$41.4 Million 1.32% of portfolio
7,000,000
Q4 2023 New
$134M
$35.5 Million 1.13% of portfolio
10,333,600
Q4 2023 Added 24.62%
$1.6B
$17.1 Million 0.54% of portfolio
850,000
Q3 2024 New
$59.2M
$15.7 Million 0.5% of portfolio
6,293,282
Q2 2024 Added 45.45%
$42.8M
$14.7 Million 0.47% of portfolio
8,902,972
Q1 2024 New
$91.8M
$14.9 Million 0.47% of portfolio
2,989,474
Q2 2023 New
$89.8M
$10.8 Million 0.34% of portfolio
16,552,417
Q1 2024 Added 93.54%
$62M
$8.25 Million 0.26% of portfolio
4,769,164
Q4 2023 Added 50.49%
$69.8M
$6.17 Million 0.2% of portfolio
1,813,633
Q3 2022 New
$71.9M
$6.17 Million 0.2% of portfolio
5,228,461
Q2 2024 Reduced 20.73%
$80.3M
$4.55 Million 0.14% of portfolio
3,853,818
Q1 2024 Reduced 43.75%
$429M
$3.15 Million 0.1% of portfolio
650,000
Q3 2022 New
$176M
$2.26 Million 0.07% of portfolio
443,221
Q4 2021 Added 5.78%
$13.7M
$1.78 Million 0.06% of portfolio
2,966,836
Q3 2024 Added 28.31%
$16.3M
$1.62 Million 0.05% of portfolio
9,544,262
Q4 2020 Added 31.75%
$110M
$1.28 Million 0.04% of portfolio
686,040
Q1 2022 Added 25.99%
Verastem Inc
-
$0 0.0% of portfolio
-
Q2 2023 New
Avalo Therapeutics Inc
-
$0 0.0% of portfolio
-
Q3 2024 New
Molecular Templates Inc
-
$0 0.0% of portfolio
-
Q1 2024 Reduced 1.84%
Vistagen Therapeutics Inc
-
$0 0.0% of portfolio
-
Q4 2023 New
Cidara Therapeutics Inc
-
$0 0.0% of portfolio
-
Q3 2024 Added 104.94%
Cg Oncology Inc
-
$0 0.0% of portfolio
-
Q3 2024 Reduced 58.87%
Engene Holdings Inc
-
$0 0.0% of portfolio
-
Q4 2023 New
Engene Holdings Inc
-
$0 0.0% of portfolio
-
Q4 2023 New
Tenax Therapeutics Inc
-
$0 0.0% of portfolio
-
Q3 2024 New
Structure Therapeutics Inc
-
$0 0.0% of portfolio
-
Q3 2024 Reduced 10.0%
Sab Biotherapeutics Inc
-
$0 0.0% of portfolio
-
Q1 2024 New

Summary

  • Portfolio
  • No. of Stocks 55
  • Current Value $3.15 Billion
  • Prior Value $3.27 Billion
  • Filing
  • Period Q3 2024
  • Filing Date November 14, 2024
  • Form Type 13F-HR
  • Activity in Q3 2024
  • New Purchases 5 stocks
  • Additional Purchases 6 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 9 stocks
Track This Portfolio

Track Bvf Inc Portfolio

Follow Bvf Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bvf Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bvf Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email